Benserazide effects on growth hormone, prolactin, and thyrotropin in normal and acromegalic man.
The effect of benserazide administration on the secretion of GH, PRL, and TSH has been considered as an index of dopamine regulatory actions. Nine acromegalic patients and nine normal subjects were given a single 125 mg oral dose of benserazide, and serum GH, PRL, and TSH were determined by RIA methods every 30 min for 4 h. Benserazide did not alter GH values either in normal subjects or in acromegalic patients. A significant increase of serum PRL was found in both groups, and the increase was similar in normoprolactinemic and in hyperprolactinemic acromegalic patients. A significant increase in TSH levels was found only in acromegalic patients. Thus, a decrease in dopamine outside the blood-brain barrier did not affect GH secretion, whereas PRL secretion was changed in the acromegalic as well as in the control group.
D000172:Acromegaly / Q000097:blood*; D000328:Adult; D001545:Benserazide / Q000494:pharmacology*; D004298:Dopamine / Q000502:physiology; D005260:Female; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D006834:Hydrazines / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D011388:Prolactin / Q000097:blood*; D013972:Thyrotropin / Q000097:blood*
D006834:Hydrazines; D001545:Benserazide; D011388:Prolactin; D013972:Thyrotropin; D013006:Growth Hormone; D004298:Dopamine